Wedbush starts Dianthus at outperform, sees DNTH103 as well-positioned (DNTH)

Wedbush has initiated coverage of Dianthus Therapeutics (NASDAQ:DNTH) with an outperform rating, stating it see the company’s drug candidate DNTH103 as well-positioned.

The investment firm estimates DNTH103 revenue reaching $599M in 2030. It added that advances in targeting and the potential for more convenient dosing will help the company differentiate itself from its peers and rivals.

Wedbush added that the company had a cash runway of $190M, which should fund operations into Q2 2026 and past key proof-of-concept data readouts.

The firm set a price target of $23 for the stock.